Iovance Biotherapeutics, Inc. appointed Corleen Roche as Chief Financial Officer, effective August 6th, 2025. Ms. Roche brings 30 years of experience in biotech and life sciences, including executive financial roles at companies like Biogen and Pfizer. She will focus on revenue growth and pipeline investments to achieve financial goals and advance the mission of developing novel therapies for cancer patients. Iovance aims to be a global leader in TIL therapies, with Amtagvi® as the first FDA-approved T cell therapy for solid tumors. For more information, visit www.iovance.com.

Contact information for investors: [email protected], 650-260-7120 ext. 150. For media inquiries: [email protected], 650-260-7120 ext. 150.

Read more at GlobeNewswire: Iovance Biotherapeutics Appoints Corleen Roche as Chief